BioCentury | Dec 27, 2019
Clinical News

Spring Bank’s HBV therapy on hold after signs of liver damage

Spring Bank’s revelation of liver toxicity in chronic HBV patients treated with inarigivir soproxil in a Phase IIb trial sent the company’s shares down 67% Thursday; however, the readout doesn’t necessarily mean that immuno-oncology therapies...
BioCentury | Jul 13, 2018
Clinical News

Filgotinib meets in Phase II for psoriatic arthritis

Gilead Sciences Inc. (NASDAQ:GILD) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) said in May that once-daily 200 mg oral filgotinib (GLPG0634, GS-6034) met the primary endpoint of improving the proportion of patients with a 20% improvement in...
BioCentury | Apr 20, 2018
Company News

Target ALS and partners launch biomarker study

Target ALS Foundation (New York, N.Y.) is partnering with the Muscular Dystrophy Association (MDA) (Chicago, Ill.), the CReATe Consortium and 10 industry partners to conduct a study to validate biomarker candidates for amyotrophic lateral sclerosis....
BioCentury | Apr 19, 2018
Company News

Target ALS, partners launch biomarker study

Target ALS Foundation is partnering with the Muscular Dystrophy Association (MDA), the CReATe Consortium and 10 industry partners to conduct a study to validate biomarker candidates for amyotrophic lateral sclerosis. The study will seek to...
BioCentury | Mar 3, 2016
Distillery Therapeutics

Therapeutics: Interferon induced with helicase C domain 1 (IFIH1; MDA5)

Cancer INDICATION: Prostate cancer Cell culture and mouse studies suggest IFIH1 could help treat prostate cancer. In a mouse prostate cancer cell line, viral vector-mediated overexpression of mouse IFIH1 decreased proliferation and increased pro-apoptotic signaling...
BioCentury | May 18, 2015
Emerging Company Profile

RIG-ged against cancer

Rigontec GmbH is incorporating lessons from over a decade of research on oligonucleotide therapeutics to develop cancer therapies targeting RIG-I , an immune-stimulating receptor related to toll-like receptors that may have more tumor-specific activity than TLRs....
BioCentury | Dec 11, 2014
Distillery Therapeutics

Indication: Endocrine/metabolic disease

...Diabetes; obesity IL-22; IL-23; IL-24 (MDA7) Mouse studies suggest IL-22 or inhibition of IL-23 and IL-24...
...In a mouse model of high-fat diet-induced obesity, IL-22 or neutralizing mAbs against IL-23 and IL-24...
BioCentury | May 26, 2014
Clinical News

Aldeyra Therapeutics preclinical data

In reconstructed human epidermis under dry skin conditions, topical 0.05% NS2 significantly reduced malondialdehyde (MDA) levels vs. untreated controls (p<0.01). Aldeyra said that MDA levels have been shown to be elevated in a variety of...
BioCentury | Apr 10, 2014
Targets & Mechanisms

Catastrophic vacuolization

...to be obtained to support an IND filing. Dent's laboratory is working on IL-24 ( MDA7...
BioCentury | Jun 3, 2013
Product Development

The DMD landscape

Three companies are vying to gain the first approved drug for Duchenne muscular dystrophy in a race that has seen one company's stock soar 309% over the past year and the other two companies file...
Items per page:
1 - 10 of 97